ApprovedFDA approval

Lifyorli (relacorilant)

Corcept Therapeutics (CORT)

Marketer take

A new option in platinum-resistant ovarian cancer after prior bevacizumab, and the same molecule faces a separate Cushing's syndrome decision on Dec 17, 2026, so watch for two brands with very different audiences.

Sponsor company
Corcept Therapeutics (CORT)
Indication
To treat platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic treatment regimens, at least one of which included bevacizumab
Therapeutic area
Oncology
Event
FDA approval
Date
Mar 25, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move